Naturally presented MHC ligands carrying glycans

Transfusion Medicine and Hemotherapy

Volumn 33, Issue 1, 2006, Pages 38-44

  Dengjel, Jörn ^a   Stevanović, Stefan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Autoimmunity; Cancer; Glycopeptide; HLA; Immunotherapy

Indexed keywords

EPITOPE; GLYCAN DERIVATIVE; GLYCOPROTEIN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

AUTOIMMUNITY; CARCINOGENESIS; CARTILAGE; CELLULAR IMMUNITY; DEAMINATION; DENDRITIC CELL; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 33644524728     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090194     Document Type: Review

References (68)

1. Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee HG: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-296.
2. York IA, Goldberg AL, Mo XY, Rock KL: Proteolysis and class I major histocompatibility complex antigen presentation. Immunol Rev 1999;172:49-66.
3. Kloetzel PM: Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII. Nat Immunol 2004;5:661-669.
4. Neefjes J: CIIV, MIIC and other compartments for MHC class II loading. Eur J Immunol 1999;29:1421-1425.
5. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC: Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364:33-39.
6. Rammensee HG, Bachmann J, Stevanovic S: MHC Ligands and Peptide Motifs. Heidelberg, Springer, 1997.
7. Engelhard VH: Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 1994;12:181-207.
8. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, Wiley DC: Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994;368:215-221.
9. Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL Jr, Boon T, Hunt DF, Engelhard VH: An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996;183:527-534.
10. Schmid DG, der Mulbe FD, Fleckenstein B, Weinschenk T, Jung G: Broadband detection electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry to reveal enzymatically and chemically induced deamidation reactions within peptides. Anal Chem 2001;73:6008-6013.
11. Meadows L, Wang W, den Haan JM, Blokland E, Reinhardus C, Drijfhout JW, Shabanowitz J, Pierce R, Agulnik AI, Bishop CE, Hunt DF, Goulmy E, Engelhard VH: The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997;6:273-281.
12. Herce RA, Field ED, den Haan JM, Caldwell JA, White FM, Marto JA, Wang W, Frost LM, Blokland E, Reinhardus C, Shabanowitz J, Hunt DF, Goulmy E, Engelhard VH: Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J Immunol 1999;163:6360-6364.
13. Haurum JS, Hoier IB, Arsequell G, Neisig A, Valencia G, Zeuthen J, Neefjes J, Elliott T: Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med 1999;190:145-150.
14. Zarling AL, Ficarro SB, White FM, Shabanowitz J, Hunt DF, Engelhard VH: Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J Exp Med 2000;192:1755-1762.
15. Lis H, Sharon N: Protein glycosylation. Structural and functional aspects. Eur J Biochem 1993;218:1-27.
16. Vance BA, Wu W, Ribaudo RK, Segal DM, Kearse KP: Multiple dimeric forms of human CD69 result from differential addition of N-glycans to typical (Asn-X-Ser/Thr) and atypical (Asn-X-cys) glycosylation motifs. J Biol Chem 1997;272:23117-23122.
17. Kornfeld R, Kornfeld S: Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 1985;54:631-664.
18. Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J: Essentials of Glycobiology. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1999.
19. Van den Steen PE, Rudd PM, Wormald MR, Dwek RA, Opdenakker G: O-linked Glycosylation in Focus. Trends in Glycoscience and Glycotechnology 2000;12:35-49.
20. Ferguson MA: Colworth Medal Lecture. Glycosylphosphatidylinositol membrane anchors: the tale of a tail. Biochem Soc Trans 1992;20:243-256.
21. Smythe C, Caudwell FB, Ferguson M, Cohen P: Isolation and structural analysis of a peptide containing the novel tyrosyl-glucose linkage in glycogenin. EMBO J 1988;7:2681-2686.
22. Corthay A, Backlund J, Holmdahl R: Role of glycopeptide-specific T cells in collagen-induced arthritis: an example how post-translational modification of proteins may be involved in autoimmune disease. Ann Med 2001;33:456-465.
23. Wells L, Vosseller K, Hart GW: Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 2001;291:2376-2378.
24. Katsuki M, Kakimoto K, Kawata S, Kotani S, Koga T: Induction of delayed-type hypersensitivity by the T cell line specific to bacterial peptidoglycans. J Immunol 1987;139:3570-3572.
25. Singhal A, Fohn M, Hakomori S: Induction of alpha-N-acetylgalactosamine- O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res 1991;51:1406-1411.
26. Ishioka GY, Lamont AG, Thomson D, Bulbow N, Gaeta FC, Sette A, Grey HM: MHC interaction and T cell recognition of carbohydrates and glycopeptides. J Immunol 1992;148:2446-2451.
27. Harding CV, Kihlberg J, Elofsson M, Magnusson G, Unanue ER: Glycopeptides bind MHC molecules and elicit specific T cell responses. J Immnnol 1993;151:2419-2425.
28. Deck B, Elofsson M, Kihlberg J, Unanue ER: Specificity of glycopeptide-specific T cells. J Immunol 1995;155:1074-1078.
29. Jensen T, Nielsen M, Gad M, Hansen P, Komba S, Meldal M, Odum N, Werdelin O: Radically altered T cell receptor signaling in glycopeptide-specific T cell hybridoma induced by antigen with minimal differences in the glycan group. Eur J Immunol 2001;31:3197-3206.
30. Jensen T, Hansen P, Galli-Stampino L, Mouritsen S, Frische K, Meinjohanns E, Meldal M, Werdelin O: Carbohydrate and peptide specificity of MHC class II-restricted T cell hybridomas raised against an O-glycosylated self peptide. J Immunol 1997;158:3769-3778.
31. Deck MB, Sjolin P, Unanue ER, Kihlberg J: MHC-restricted, glycopeptide-specific T cells show specificity for both carbohydrate and peptide residues. J Immunol 1999;162:4740-4744.
32. Jensen T, Hansen P, Faurskov NA, Meldal M, Komba S, Werdelin O: Shared structural motifs in TCR of glycopeptide-recognizing T cell hybridomas. Eur J Immunol 1999;29:2759-2768.
33. Haurum JS, Arsequell G, Lellouch AC, Wong SY, Dwek RA, McMichael AJ, Elliott T: Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med 1994;180:739-744.
34. Haurum JS, Tan L, Arsequell G, Frodsham P, Lellouch AC, Moss PA, Dwek RA, McMichael AJ, Elliott T: Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition. Eur J Immunol 1995;25:3270-3276.
35. Speir JA, Abdel-Motal UM, Jondal M, Wilson IA: Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Immunity 1999;10:51-61.
36. Glithero A, Tormo J, Haurum JS, Arsequell G, Valencia G, Edwards J, Springer S, Townsend A, Pao YL, Wormald M, Dwek RA, Jones EY, Elliott T: Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity. Immunity 1999;10:63-74.
37. Abdel-Motal UM, Berg L, Rosen A, Bengtsson M, Thorpe CJ, Kihlberg J, Dahmen J, Magnusson G, Karlsson KA, Jondal M: Immunization with glycosylated Kb-binding peptides generates carbohydrate-specific, unrestricted cytotoxic T cells. Eur J Immunol 1996;26:544-551.
38. Apostolopoulos V, Yuriev E, Ramsland PA, Halton J, Osinski C, Li W, Plebanski M, Paulsen H, McKenzie IF: A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci U S A 2003;100:15029-15034.
39. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL: Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993;178:27-47.
40. Chicz RM, Lane WS, Robinson RA, Trucco M, Strominger JL, Gorga JC: Self-peptides bound to the type I diabetes associated class II MHC molecules HLA-DQ1 and HLA-DQ8. Int Immunol 1994;6:1639-1649.
41. Dengjel J, Rammensee HG, Stevanovic S: Glycan side chains on naturally presented MHC class II ligands. J Mass Spectrom 2005;40:100-104.
42. Vlad AM, Muller S, Cudic M, Paulsen H, Otvos L Jr, Hanisch FG, Finn OJ: Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 2002;196:1435-1446.
43. Dudler T, Altmann F, Carballido JM, Blaser K: Carbohydrate-dependent, HLA class II-restricted, human T cell response to the bee venom allergen phospholipase A2 in allergic patients. Eur J Immunol 1995;25:538-542.
44. Lankat-Buttgereit B, Tampe R: The transporter associated with antigen processing: function and implications in human diseases. Physiol Rev 2002;82:187-204.
45. Hudrisier D, Riond J, Mazarguil H, Oldstone MB, Gairin JE: Genetically encoded and post-translationally modified forms of a major histocompatibility complex class I-restricted antigen bearing a glycosylation motif are independently processed and co-presented to cytotoxic T lymphocytes. J Biol Chem 1999;274:36274-36280.
46. Kastrup IB, Stevanovic S, Arsequell G, Valencia G, Zeuthen J, Rammensee HG, Elliott T, Haurum JS: Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo. Tissue Antigens 2000;56:129-135.
47. Selby M, Erickson A, Dong C, Cooper S, Parham P, Houghton M, Walker CM: Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules. J Immunol 1999;162:669-676.
48. Suzuki T, Park H, Kitajima K, Lennarz WJ: Peptides glycosylated in the endoplasmic reticulum of yeast are subsequently deglycosylated by a soluble peptide: N-glycanase activity. J Biol Chem 1998;273:21526-21530.
49. Bäcklund J, Carlsen S, Hoger T, Holm B, Fugger L, Kihlberg J, Burkhardt H, Holmdahl R: Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci U S A 2002;99:9960-9965.
50. Wooley PH, Luthra HS, Stuart JM, David CS: Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med 1981;154:688-700.
51. Holmdahl R, Andersson M, Goldschmidt TJ, Gustafsson K, Jansson L, Mo JA: Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol Rev 1990;118:193-232.
52. Ranges GE, Sriram S, Cooper SM: Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 1985;162:1105-1110.
53. Goldschmidt TJ, Jansson L, Holmdahl R: In vivo elimination of T cells expressing specific T-cell receptor V beta chains in mice susceptible to collagen-induced arthritis. Immunology 1990;69:508-514.
54. Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R: T cell recognition of carbohydrates on type II collagen. J Exp Med 1994;180:745-749.
55. Corthay A, Backlund J, Broddefalk J, Michaelsson E, Goldschmidt TJ, Kinlberg J, Holmdahl R: Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur J Immunol 1998;28:2580-2590.
56. Dzhambazov B, Holmdahl M, Yamada H, Lu S, Vestberg M, Holm B, Johnell O, Kihlberg J, Holmdahl R: The major T cell epitope on type II collagen is glycosylated in normal cartilage but modified by arthritis in both rats and humans. Eur J Immunol 2005;35:357-366.
57. Meezan E, Wu HC, Black PH, Robbins PW: Comparative studies on the carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. II. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry 1969;8:2518-2524.
58. Dube DH, Bertozzi CR: Glycans in cancer and inflammation - potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005;4:477-488.
59. Franco A: CTL-based cancer preventive/therapeutic vaccines for carcinomas: role of tumour-associated carbohydrate antigens. Scand J Immunol 2005;61:391-397.
60. Cao Y, Stosiek P, Springer GF, Karsten U: Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem Cell Biol 1996;106:197-207.
61. Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky S, Livingston PO, Scher HI: Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J Clin Oncol 2003;21:4292-4298.
62. Galli-Stampino L, Meinjohanns E, Frische K, Meldal M, Jensen T, Werdelin O, Mouritsen S: T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res 1997;57:3214-3222.
63. Gendler SJ, Spicer AP: Epithelial mucin genes. Annu Rev Physiol 1995;57:607-634.
64. Baldus SE, Hanisch FG: Biochemistry and pathological importance of mucin-associated antigens in gastrointestinal neoplasia. Adv Cancer Res 2000;79:201-248.
65. Gad M, Jensen T, Gagne R, Komba S, Daugaard S, Kroman N, Meldal M, Werdelin O: MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue. Eur J Immunol 2003;33:1624-1632.
66. Zhao XJ, Cheung NK: GD2 oligosaccharide: target for cytotoxic T lymphocytes. J Exp Med 1995;182:67-74.
67. Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA: Glycosylation and the immune system. Science 2001;291:2370-2376.
68. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB: Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995;1:237-243.